BMRA

Biomerica is a $4.9M-market-cap diagnostics company whose numbers describe a business fighting for survival, not one compounding value. FY2025 revenue of $5.31M actually fell 1.9% YoY and sits far below the $18.9M COVID-era spike of FY2022, so the top line is shrinking, not scaling. The deeper problem is unit economics: gross profit was just $498K on $5.31M of sales — a 9.4% gross margin — meaning the core product barely covers its own cost of goods before a dollar of R&D, sales or overhead. That drives a -96.7% operating margin, a -$4.97M net loss, and a punishing -121.1% ROE. Five straight years of net losses and a -$53.2M accumulated deficit confirm this is structural, not a one-off.

Liquidity is the binding constraint. The 10-K discloses $3,841K of cash used in operations in FY2025, against only $2.40M of cash on the balance sheet (down 42.5% YoY) — well under a year of runway on the core burn. Management has plugged the gap by selling stock: $2,015K of net ATM proceeds in FY2025 plus a July 2025 $1.1M ERC tax refund. But the filing itself flags the trap — because public float is under $75M, Form S-3 Instruction I.B.6 caps 12-month shelf sales at one-third of float, leaving only ~$232K of headroom disclosed at filing. So the very lifeline (dilutive equity issuance) is regulatorily throttled, and shareholders face continued dilution on top of what already looks like a reverse split (shares outstanding down 83.3% to 2.82M).